News

In rare cases, stroke-like symptoms, such as tingling in the face and the left arm, can occur during an acute attack of hereditary angioedema (HAE), a case study reports. The patient, a woman in her 30s, developed facial swelling and abdominal pain. All her symptoms resolved with treatment with…

A fully assembled, prefilled syringe form of Takeda’s Takhzyro (lanadelumab), approved to prevent swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE), is now available in the U.S. “HAE attacks are unpredictable, debilitating and in some cases life-threatening, adding uncertainty and complexity to the…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

A man who had been treated with the blood pressure medication losartan for 20 years experienced sudden angioedema after upping the medication’s dose, according to a recent case report. “This is the first documented case of angioedema presenting in a dose-dependent manner with losartan use. We hope that our…

The one-year Phase 3 SPRING study evaluating the safety, efficacy, and pharmacological properties of Takhzyro (lanadelumab) in children with hereditary angioedema (HAE), ages 2 to 11, succeeded in meeting its goals, Takeda, which markets the treatment, announced. Based on these findings, the company plans to file applications…

The National Organization for Rare Disorders (NORD) has updated its State Report Card to make it more digitally friendly and added telehealth to its categories of rare disease policy issues in a nod to its increased use during the ongoing COVID-19 pandemic. NORD’s report card project began seven…

Six warning signs were present in a group of patients with hereditary angioedema (HAE) due to a deficiency in C1-inhibitor (C1-INH), as reported in a recent study from Brazil. Dubbed H4AE to assist in recalling, the warning signs are hereditary (H), recurrent angioedema (A), abdominal pain (A), absence of…

Takhzyro (lanadelumab) led to significant benefits for patients with hereditary angiodema (HAE) in France who received the therapy as part of an early-access program prior to its approval in Europe, a study has found. The treatment “reduced attack rates, improved quality of life, and was generally well tolerated,”…

Patients with hereditary angioedema (HAE) are more likely to develop comorbidities, or co-existing conditions, such as cardiovascular and autoimmune diseases than the general population, a Swedish database study reports. The findings highlight the need for awareness and prevention of these conditions in patients with HAE, according to researchers. The…

Takhzyro (lanadelumab) has been approved in Japan to prevent acute swelling attacks in people, 12 and older, with hereditary angioedema (HAE). An estimated 2,000 to 3,000 people with HAE live in Japan, but fewer than 500 have been diagnosed due to a lack of awareness, according to…